WT1 and glioblastoma: A WT1- and cytomegalovirus phosphoprotein 65 RNA (CMV pp65)-based DC vaccine is generated from a single tumor antigen, both of which have demonstrated efficiency in improving the PFS and OS of GBM patients in phase I clinical trials (120–123).